This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Other Connective and Soft Tissue기타 결합조직 및 연조직의 악성신생물 (연조직육종)

Classification codesC49 (ICD-10) — C49.0 head and neck, C49.1 upper limb, C49.2 lower limb, C49.3 thorax, C49.4 abdomen, C49.5 pelvis, C49.6 trunk, unspecified, C49.8 overlapping, C49.9 unspecified
SynonymsSoft Tissue Sarcoma (STS), Liposarcoma, Leiomyosarcoma, Rhabdomyosarcoma, Synovial sarcoma, Fibrosarcoma, undifferentiated pleomorphic sarcoma (UPS)
Adult onsetNot low — possible at any adult age; varies by type (rhabdomyosarcoma: children and adolescents; leiomyosarcoma: middle-aged adults in their 50s–60s)
Special Copayment ReductionV193 — 5 years from the date of cancer patient registration, copayment 5%
1. HistoryStout's STS classification (1953), evolution of the WHO classification, the beginning of the era of molecular targeted therapy
2. CausesRadiation (10%), genetic syndromes (NF1, Li-Fraumeni, Gardner), viruses (HHV-8/KS)
3. GeneticsMDM2/CDK4 amplification (liposarcoma), SS18-SSX (synovial sarcoma), SYT-SSX, EWSR1, PAX-FOXO
4. EpidemiologyAbout 1% of all malignancies; estimated about 1,500–2,000 cases per year in Korea; limbs 50–60%
5. PathophysiologyMalignant transformation of mesenchymal stem cells; generation of fusion genes by chromosomal translocation; complex karyotype
6. SymptomsPainless soft tissue mass; pain and nerve compression are signs of progression; respiratory symptoms with lung metastasis
7. SignsDeep mass 5cm or larger; hard, fixed mass; signs of compression of surrounding nerves and vessels
8. ScreeningNo general population screening; annual whole-body MRI in Li-Fraumeni; MRI for high-risk NF1
9. DiagnosisMRI/PET-CT/core needle biopsy/IHC/FISH and NGS molecular testing/FNCLCC grade
10. TreatmentWide excision (R0), radiation, doxorubicin+ifosfamide, pazopanib, trabectedin, eribulin
11. Prognosis5-year survival 60–80% (localized); median survival about 16 months for metastatic disease
12. PreventionMinimizing radiation, counseling for genetic syndromes, avoiding unnecessary radiotherapy, follow-up of high-risk groups
13. ReferencesKey references

1. History

Soft tissue sarcoma (STS) is a malignancy arising from connective tissue, and its history is closely linked to the development of pathology. In the 19th century, Rudolf Virchow was the first to systematically classify soft tissue tumors from the standpoint of cellular pathology. However, the modern classification of soft tissue sarcoma began with the 1953 classification system of Arthur Purdy Stout. He systematically classified liposarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma and others based on histological features, and this classification system later became the basis of the WHO classification.

In the late 20th century, the introduction of electron microscopy and immunohistochemistry made it possible to identify the cell of origin of tumors more precisely. The 1996 WHO classification of soft tissue tumors greatly expanded the histologic types, and through revisions in 2002, 2013 and 2020, molecular genetic features were integrated into the classification criteria. In particular, the era of molecular diagnosis opened with the discovery of specific chromosomal translocations, such as the SS18-SSX fusion gene in synovial sarcoma (1994) and ASPSCR1-TFE3 in alveolar soft part sarcoma (2001).

An important milestone in the history of treatment was the introduction of limb-salvage surgery in the 1970s. Until then, amputation was the standard for limb sarcomas, but Rosenberg et al. showed in 1982 that limb-salvage surgery combined with radiotherapy achieves survival equivalent to amputation. In systemic therapy, doxorubicin (FDA approval 1974) and ifosfamide (1988) were established as standard anticancer drugs. In 2012, pazopanib received FDA approval for second-line treatment of non-adipocytic soft tissue sarcoma, and in 2016 eribulin was approved for liposarcoma and trabectedin for liposarcoma/leiomyosarcoma.

In Korea, major institutions such as Seoul National University Hospital, Samsung Medical Center, Severance Hospital and Asan Medical Center operate specialized soft tissue sarcoma clinics and multidisciplinary teams, and the Korean Sarcoma Study Group leads domestic clinical research.

2. Causes

Most soft tissue sarcomas arise sporadically without a clear cause, but in some cases the following risk factors are identified.

Radiation exposure

Radiation-induced sarcoma can arise at sites previously treated with radiotherapy, accounting for about 5–10% of all STS. The latency is usually 10–20 years. Radiation-induced sarcoma has been reported after radiotherapy for breast cancer, cervical cancer, lymphoma and others. Radiation-induced sarcomas are often high grade and have a poor prognosis.

Genetic predisposition

Viral infection

Kaposi sarcoma is caused by human herpesvirus 8 (HHV-8, KSHV), and the risk is greatly increased in patients with HIV/AIDS. HHV-8 promotes the survival of tumor cells through the virus-encoded FLICE-inhibitory protein (vFLIP) and the K1 protein.

Other causes

Lymphedema (lymphangiosarcoma arising in chronic lymphedema; Stewart-Treves syndrome) and exposure to foreign substances (Thorotrast, chemicals) have rarely been reported.

3. Genetics

Soft tissue sarcomas are divided into two main groups according to genomic abnormalities.

Simple karyotype sarcomas: specific gene rearrangements

This group has relatively simple genomic abnormalities (particularly specific chromosomal translocations), which are highly valuable as diagnostic biomarkers.

Tumor typeSpecific gene rearrangement/amplification
Synovial sarcomaSS18-SSX1/SSX2(t(X;18))
Myxoid/round cell liposarcomaFUS-DDIT3 (t(12;16)) or EWSR1-DDIT3
Well-differentiated/dedifferentiated liposarcomaMDM2/CDK4 amplification (12q13-15)
Alveolar rhabdomyosarcomaPAX3-FOXO1 (t(2;13)) or PAX7-FOXO1 (t(1;13))
Ewing sarcomaEWSR1-FLI1 (t(11;22)) or EWSR1-ERG
CIC-rearranged sarcomaCIC-DUX4(t(4;19))
BCOR-rearranged sarcomaBCOR-CCNB3(inv X)

Complex karyotype sarcomas

Leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS) and others have complex karyotypic abnormalities and numerous somatic mutations, and there are no specific molecular markers for diagnosis. In these, abnormalities of tumor suppressor genes such as TP53, RB1, ATRX, PTEN are common. Pharmacogenomically, CDK4/CDK6 inhibitors (palbociclib, abemaciclib) are attracting clinical interest in MDM2/CDK4-amplified liposarcoma, and NTRK fusions are targets of NTRK inhibitors (larotrectinib, entrectinib).

4. General epidemiology

Soft tissue sarcoma is a rare tumor accounting for about 1% of all malignancies, but it is a heterogeneous group comprising more than 50 histologic subtypes. In the United States, about 13,000 cases are newly diagnosed each year, and about 5,000 people die of it annually. In Korea, about 1,500–2,000 cases are estimated to be newly diagnosed each year.

Age at onset varies by type. Rhabdomyosarcoma occurs mainly in children and adolescents (under 5 years and teens), and Ewing sarcoma is common in the 10s–30s. In contrast, leiomyosarcoma, liposarcoma and UPS occur mainly in the 50s–70s. Overall, the sex difference in soft tissue sarcoma is small, but some types show differences (e.g., uterine leiomyosarcoma in women, gastrointestinal stromal tumor (GIST) slightly male-predominant). The main sites of occurrence are the limbs (especially the thigh, 50–60%), retroperitoneum (15%), trunk (10–15%) and head and neck (10%). About 60% arise in a deep (subfascial) location.

5. Pathophysiology

The pathogenesis of soft tissue sarcoma is understood as following two main pathways according to histologic type.

Pathogenesis by specific chromosomal translocation

In 'simple karyotype' sarcomas such as synovial sarcoma, Ewing sarcoma and alveolar rhabdomyosarcoma, specific chromosomal translocations occur and create new fusion genes. For example, the SS18-SSX fusion protein of synovial sarcoma disrupts the function of a chromatin remodeling complex (PBAF), inducing tumorigenesis. The EWSR1-FLI1 fusion transcription factor of Ewing sarcoma regulates various oncogenes through aberrant enhancer activation via GGAA microsatellites. These fusion genes often arise in mesenchymal stem cells, and a single genetic event alone can produce a malignant phenotype.

Pathogenesis by complex genomic abnormalities

'Complex karyotype' sarcomas such as leiomyosarcoma, UPS and dedifferentiated liposarcoma arise through the accumulation of numerous somatic mutations, copy number alterations and chromosomal instability. Loss of function of cell cycle regulatory genes such as TP53, RB1 plays a key role. In radiation-induced sarcoma, DNA double-strand breaks caused by radiation are the trigger for these complex genomic abnormalities.

6. Symptoms

The clinical symptoms of soft tissue sarcoma vary with the tumor's site, size, depth and involvement of surrounding structures.

Symptoms related to the primary tumor

Symptoms related to metastasis

7. Signs

The main signs on physical examination suggesting a malignant soft tissue tumor are as follows.

8. Screening

No standard screening program for soft tissue sarcoma has been established for the general population. However, systematic monitoring is recommended in patients with high-risk genetic syndromes.

Monitoring of high-risk groups

Follow-up after radiotherapy

Because radiation-induced sarcoma can arise at sites treated with radiotherapy, attention should be paid to soft tissue abnormalities in the irradiated area during long-term follow-up after treatment.

9. Diagnosis

The diagnosis of soft tissue sarcoma rests on three pillars—radiology, histopathology and molecular genetics—and a multidisciplinary approach at a specialized soft tissue sarcoma center is essential.

Imaging tests

Histopathological diagnosis

FNCLCC grading

Under the grading system of the French Federation of Cancer Centers (FNCLCC), scores for tumor differentiation (1–3 points), mitotic index (1–3 points) and necrosis (0–2 points) are summed and classified as grade I (low grade, 2–3 points), II (intermediate grade, 4–5 points) or III (high grade, 6–8 points). Grade is central to predicting prognosis and deciding on adjuvant treatment.

10. Treatment

The core of soft tissue sarcoma treatment is complete surgical resection (R0), and multidisciplinary treatment planning at a specialized soft tissue sarcoma center greatly improves prognosis.

Surgical treatment

Wide resection aims for negative margins (R0), and margin status is the single most important prognostic factor. For limb sarcomas, limb-salvage surgery is considered first, and vascular reconstruction, nerve preservation or grafting may be performed to preserve function. Re-resection is also actively considered for recurrent resectable tumors.

Radiation therapy

Adjuvant radiotherapy (total 50–66 Gy) is given for high-grade sarcomas and after resection with positive margins (R1/R2) or close margins. Preoperative radiotherapy (50 Gy) is used to reduce the extent of surgery and improve resectability; compared with postoperative radiotherapy it has more wound complications but is advantageous for long-term functional preservation.

Chemotherapy

11. Prognosis

Prognostic factorsDetails
5-year survival of localized high-grade STS60–80% (R0 resection + radiotherapy)
Median overall survival of metastatic STSAbout 12–18 months
With positive margins (R1)Local recurrence rate about 30–40%, reduced survival
High grade (FNCLCC grade 3)High rate of distant metastasis (about 30–50%)
Tumor size >5 cmPoor prognostic factor
Deep locationPoor prognostic factor (higher risk of distant metastasis than superficial)

Poor prognostic factors include high grade, large tumor size (>5 cm), deep location, positive margins, distant metastasis, radiation induction, and head and neck or retroperitoneal origin. The lung is the most common site of distant metastasis (about 40–50%). Myxoid liposarcoma commonly metastasizes to the spine and abdominal cavity. Synovial sarcoma has a better prognosis than soft tissue sarcomas in general.

12. Prevention

Minimizing radiation exposure

Management of genetic syndromes

Prevention of occupational exposure

13. References

  1. Doxorubicin & Ifosfamide combination in advanced soft tissue sarcoma. SWAG Cancer Alliance NHS. 2025.
  2. Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced STS. PMC8648074. 2021.
  3. Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk STS. PMC8541966. 2021.
  4. Role of CDK4 as prognostic biomarker in STS. Exp Hematol Oncol. 2024. PMC.
  5. Abstract: Molecular characteristics of CDK4 and/or MDM2 amplification in Chinese STS. AACR. 2021.
  6. WHO Classification of Soft Tissue and Bone Tumours. 5th ed. IARC Press. 2020.
  7. ESMO Clinical Practice Guidelines: Soft Tissue and Visceral Sarcomas. Ann Oncol. 2021.
  8. NCCN Guidelines: Soft Tissue Sarcoma. Version 2.2024.
  9. National Cancer Information Center. Cancer statistics in Korea 2023. 2025.
  10. Korean Sarcoma Study Group data. 2024.